Výsledky vyhledávání - "Radostina Gencheva"

Abstract OT1-03-03: Investigating circulating lncRNAs in breast cancer patients on neoadjuvant systemic therapy

Autor: Georgi Zhbantov, Boris Krastev, Anika Ivanova, Georgi Stamenov, Radostina Gencheva, Spartak Valev, Teodora Karanikolova, Mila P. Petrova, Constanta Timcheva, Ivaylo Stoykov

Publikováno v: Cancer Research. 80:OT1-03

Background. In cells long non-coding RNAs (lncRNAs) control gene expression through various mechanisms, acting on different biological levels: chromatin remodeling, regulation of transcription, posttranscriptional modification. LncRNAs could also be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::16a7adb05979dcc07948e2c05e0586f5
https://doi.org/10.1158/1538-7445.sabcs19-ot1-03-03

Zobrazit plný text záznamu

Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer

Autor: Ivan Donev, Constanta Timcheva, Vera G. Megdanova, Mariyana I. Eneva, Velko Minchev, Bozhil Robev, Georgi Zhbantov, Geogi N. Valchev, Mila P. Petrova, Teodora Karanikolova, Nikolay Conev, Margarita S. Taushanova, Boian Pavlov, Eleonora Dimitrova, Anika Ivanova, Radostina Gencheva, Marsella Boneva, Maria Radanova

Publikováno v: Clin Exp Immunol

Summary The aim of this multi-center retrospective study was to evaluate the incidence of hyperprogressive disease (HPD) after second-line treatment with pembrolizumab in patients (n = 167) with metastatic non-small-cell lung cancer (NSCLC) whose tum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b6ba4e8acd01ffd4696cdf1bb9c2761
https://pubmed.ncbi.nlm.nih.gov/32757277

Zobrazit plný text záznamu

Plný text ve formátu HTML

Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer

Autor: Teodora Karanikolova, Georgi Zhbantov, Radostina Gencheva, Mariyana I. Eneva, Krassimir D. Koynov, Iva I Sarbianova, Anika Ivanova, Mila P. Petrova, Jeliazko Iliev Arabadjiev, Eleonora Dimitrova, Ivan Donev, Constanta Timcheva, Spartak Valev, Nikolay Conev

Publikováno v: Bioscience trends. 14(1)

The aim of this multicentric retrospective study is to evaluate the predictive and prognostic performance of neutrophil to lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and their dynamics in patients with non-small cell lung cancer (NSCLC)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a700c76931269a0cb626137a780a922
https://pubmed.ncbi.nlm.nih.gov/32023563

Zobrazit plný text záznamu

Autor: Milena Peruhova, Boris Krastev, Monika Peshevska-Sekulovska, Georgi Nikolaev, Stefan Lozenov, Radostina Gencheva, Tsvetelina Velikova

Publikováno v: International Journal of Molecular Sciences, Vol 22, Iss 1754, p 1754 (2021)
International Journal of Molecular Sciences

The interplay between drugs and microbiota is critical for successful treatment. An accumulating amount of evidence has identified the significant impact of intestinal microbiota composition on cancer treatment response, particularly immunotherapy. T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02a51a1228d23172b37eacb499c9bc2c
https://doi.org/10.3390/ijms22041754

Zobrazit plný text záznamu

High neutrophil to lymphocyte ratio as a predictor for hyperprogressive disease in patients with metastatic non-small cell lung cancer treated with pembrolizumab as a second line

Autor: Teodora Karanikolova, Nikolay Conev, Krassimir D. Koynov, Polya Penkova, Ivan Donev, Konstanta Velinova Timcheva, Mariyana I. Eneva, Georgi Zhbantov, Iva I Sarbianova, Radostina Gencheva, Spartak Valev, Anika Ivanova, M. Petrova, Jeliazko Iliev Arabadjiev, Eleonora Dimitrova

Publikováno v: Journal of Clinical Oncology. 38:e21546-e21546

e21546 Background: In this study we evaluated the incidence of early non-responders (which are potential hyper-progressors (HP)) and its relation to Neutrophil-Lymphocyte Ratio (NLR), Platelet-Lymphocyte Ratio (PLR) as well as their dynamics in patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::039cbd781ce3fa4bab4edfb6e95ad567
https://doi.org/10.1200/jco.2020.38.15_suppl.e21546

Zobrazit plný text záznamu

Sarcopenia as a negative predictive marker for treatment with pembrolizumab as a second line in patients with metastatic non-small cell lung cancer

Autor: M. Petrova, Constanta Timcheva, Eleonora Dimitrova, Teodora Karanikolova, Anika Ivanova, Nikolay Conev, Radostina Gencheva, Boian Pavlov, Marsella Boneva, Spartak Valev, Georgi Zhbantov, Velko Minchev, Bozhil Robev, Ivan Donev, Gerogi Valchev

Publikováno v: Journal of Clinical Oncology. 38:e21541-e21541

e21541 Background: In this multicentric retrospective study we evaluated the incidence of clinical benefit rate (CBR) and its relation to Neutrophil-Lymphocyte Ratio (NLR) and psoas major muscle area (PMMA), as well as their dynamics in patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dedfb04837b4aa4f9c6ca7d5c5d0ad63
https://doi.org/10.1200/jco.2020.38.15_suppl.e21541

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání